MedTrace Logo

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

NCT02553798 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 564

Last updated 2021-08-25

Study results available
· View outcomes & findings →

Summary

This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.

Conditions

  • Hyperhidrosis

Interventions

DRUG

Glycopyrronium Topical Wipes

Glycopyrronium Topical Wipes

Sponsors & Collaborators

  • Journey Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Lynne Deans, MT · Dermira, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02553798 on ClinicalTrials.gov